Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
$0.01
+2.5%
$0.01
$0.00
$0.04
N/AN/A101,875 shs13,206 shs
Barinthus Biotherapeutics plc stock logo
BRNS
Barinthus Biotherapeutics
$0.86
+3.5%
$0.85
$0.64
$2.34
$34.65M-0.836,766 shs59,839 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
+5.33%0.00%+9.72%-28.18%-16.84%
Barinthus Biotherapeutics plc stock logo
BRNS
Barinthus Biotherapeutics
+26.45%-7.08%+0.49%-19.71%-62.58%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
Barinthus Biotherapeutics plc stock logo
BRNS
Barinthus Biotherapeutics
2.9525 of 5 stars
3.53.00.00.03.80.81.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
0.00
N/AN/AN/A
Barinthus Biotherapeutics plc stock logo
BRNS
Barinthus Biotherapeutics
3.00
Buy$5.17501.47% Upside

Current Analyst Ratings Breakdown

Latest 1AE, BRNS, ATNFW, and GWP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/24/2025
Barinthus Biotherapeutics plc stock logo
BRNS
Barinthus Biotherapeutics
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/21/2025
Barinthus Biotherapeutics plc stock logo
BRNS
Barinthus Biotherapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/AN/AN/A
Barinthus Biotherapeutics plc stock logo
BRNS
Barinthus Biotherapeutics
$14.97M2.31N/AN/A$4.85 per share0.18
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/A0.00N/AN/AN/AN/AN/A
Barinthus Biotherapeutics plc stock logo
BRNS
Barinthus Biotherapeutics
-$73.35M-$1.64N/AN/AN/AN/A-34.26%-29.30%8/14/2025 (Estimated)

Latest 1AE, BRNS, ATNFW, and GWP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2025Q1 2025
Barinthus Biotherapeutics plc stock logo
BRNS
Barinthus Biotherapeutics
-$0.34-$0.49-$0.15-$0.49N/AN/A
3/20/2025Q4 2024
Barinthus Biotherapeutics plc stock logo
BRNS
Barinthus Biotherapeutics
-$0.50-$0.51-$0.01-$0.51N/A$14.97 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/AN/A
Barinthus Biotherapeutics plc stock logo
BRNS
Barinthus Biotherapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/A
Barinthus Biotherapeutics plc stock logo
BRNS
Barinthus Biotherapeutics
N/A
8.93
8.93

Institutional Ownership

CompanyInstitutional Ownership
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/A
Barinthus Biotherapeutics plc stock logo
BRNS
Barinthus Biotherapeutics
25.20%

Insider Ownership

CompanyInsider Ownership
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/A
Barinthus Biotherapeutics plc stock logo
BRNS
Barinthus Biotherapeutics
10.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
7N/AN/ANot Optionable
Barinthus Biotherapeutics plc stock logo
BRNS
Barinthus Biotherapeutics
10740.34 million37.01 millionN/A

Recent News About These Companies

William Blair Remains a Buy on Barinthus Biotherapeutics (BRNS)
Barinthus announces strategic focus in I&I, provides financial update
Barinthus Biotherapeutics Appoints New Chief Scientific Officer

Media Sentiment Over Time

180 Life Sciences stock logo

180 Life Sciences NASDAQ:ATNFW

$0.0081 +0.00 (+2.53%)
As of 09:38 AM Eastern

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

Barinthus Biotherapeutics stock logo

Barinthus Biotherapeutics NASDAQ:BRNS

$0.86 +0.03 (+3.49%)
Closing price 03:59 PM Eastern
Extended Trading
$0.84 -0.02 (-2.21%)
As of 05:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.